A web-based Personalized Nutrition Advisor (PNA) dashboard tested alongside GLP-1 receptor agonist (GLP-1 RA) therapy in 78 overweight adults (74% women, mean BMI ≥28) sustained an average -13.3% weight loss achieved over roughly 10 months of pharmacotherapy, with negligible additional change (-0.2%, SD 2.5%) across the 12-week digital counseling intervention. The tool integrated body weight measurements, dietary logs, and physical activity data to generate individualized caloric and nutritional recommendations delivered by dietitians via 3–5 remote consultations. Notably, 21% of participants suspended GLP-1 RAs due to drug shortages yet maintained weight stability. Dietitians rated usability as moderate (62% on the Healthcare Systems Usability Scale).
The finding arrives at a critical juncture: GLP-1 RA prescriptions have surged globally, yet structured dietary support remains inconsistently delivered and under-resourced. This pilot addresses a genuine clinical gap — what happens nutritionally when expensive pharmacotherapy must pause or end. The weight maintenance result during drug shortages is the most clinically provocative signal here, though the absence of a control group makes causal attribution impossible. The moderate usability score from dietitians is an honest limitation; tools rated below 70 on usability scales typically face adoption barriers in real-world clinical workflows. With only 78 participants in a single-center Swiss pilot, generalizability is constrained. Still, this represents an important proof-of-concept: structured digital nutrition support could buffer GLP-1 RA discontinuation effects. Larger randomized trials are warranted before clinical integration.
